You're underestimating Galera's GC4419. Their phase 2 data was far more compelling than ours and the FDA agrees (they got BTD, we did not). We would be in serious trouble if B-OM was not a mouth rinse rather than an IV.
Prior to the Galera results, B-OM was going to waltz into a bluesky opportunity with superior efficacy and delivery method as compared to everything including the Soligenix drug. GC4419 will succeed in phase 3 and will put a significantly higher floor under the standard of care for OM. Galera has added considerable risk to anyone looking to buy/partner B-OM because of this. I wouldn't be surprised if this is part of the reason why we have not partnered it yet - I would guess the offers are lower than we would like with competition and no BTD.
If we had double the number of patients in our B-OM phase 2 or had cleaner results this situation would be looking more in our favor. For now it's a coin toss though. Fortunately we have the superior delivery method.
News 
Market Data 
Discover 
AI
